4D Molecular Therapeutics (FDMT) vs Pharming Group N.V. (PHAR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
4D Molecular Therapeutics (FDMT) has outperformed Pharming Group N.V. (PHAR) over the past year, gaining 31.5% versus a loss of 33.7%. Over five years, PHAR leads with a +1.0% price change compared with -53.5% for FDMT. 4D Molecular Therapeutics is the larger company by market cap ($701.6 million vs $674.5 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | FDMT | PHAR |
|---|---|---|
| Share price | $12.70 | $9.53 |
| Market cap | $701.60M | $674.52M |
| 1-day change | +0.87% | -1.24% |
| YTD return | +69.33% | -46.07% |
| 1-year return | +31.47% | -33.68% |
| 5-year return | -53.51% | +0.95% |
| P/E ratio (TTM) | — | 73.31 |
| Forward P/E | — | 31.04 |
| EPS (TTM) | $-2.63 | $0.13 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $16.93 | $21.34 |
| 52-week low | $6.96 | $9.44 |
| Distance from 52-week high | -24.99% | -55.34% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +121.18% | +260.44% |
| Average volume | 926.78K | 22.84K |
| Shares outstanding | 55.24M | 70.78M |
| Employees | 196 | 407 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- FDMT has outperformed PHAR by 65.2 percentage points over the past year.
About 4D Molecular Therapeutics
FDMT stock →4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States. The company's lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEGF from the retina with intravitreal injection, as well as for treating wet age-related macular degeneration and diabetic macular edema.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 196 employees
About Pharming Group N.V.
PHAR stock →Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.
Health Care · Biotechnology: Pharmaceutical Preparations · 407 employees
FDMT vs PHAR FAQ
Which is bigger, 4D Molecular Therapeutics or Pharming Group N.V.?
4D Molecular Therapeutics (FDMT) is larger, with a market capitalization of $701.60M compared with $674.52M for Pharming Group N.V. (PHAR).
Which stock has performed better over the past year, FDMT or PHAR?
FDMT returned +31.47% over the past 12 months, compared with -33.68% for PHAR (price return, excluding dividends). Past performance does not predict future results.
Are 4D Molecular Therapeutics and Pharming Group N.V. in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for 4D Molecular Therapeutics and Biotechnology: Pharmaceutical Preparations for Pharming Group N.V..